Investing.com - Evelo Biosciences (NASDAQ: EVLO) reported first quarter EPS of $-0.21, $0.07 better than the analyst estimate of $-0.28. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Evelo Biosciences's stock price closed at $0.30. It is down -83.43% in the last 3 months and down -90.91% in the last 12 months.
Evelo Biosciences saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Evelo Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, Evelo Biosciences's Financial Health score is "weak performance".
Check out Evelo Biosciences's recent earnings performance, and Evelo Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar